EUVIMEDEUVIMED entdecken
Crossref

Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome

Eiichiro Saito, Atsushi Oura, Tetsuya Kyo, Shun Ishigaki, Hitomi Kamei, Yuki Nakamura, Jun Soma, Izaya Nakaya

Clinical and Experimental Nephrology · 2024

DOI: 10.1007/s10157-024-02508-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Eiichiro Saito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Morioka, Iwate, 020-0066, Japan. Hauptthemen laut MEDLINE: Rituximab, Nephrotic Syndrome, Recurrence, Glucocorticoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rituximab is widely used in patients with steroid-dependent nephrotic syndrome. However, information on the effect of long-term rituximab treatment is limited. This study examined the efficacy of rituximab during and after treatment in adult patients with steroid-dependent nephrotic syndrome. METHODS: This retrospective cohort study included 30 patients with steroid-dependent nephrotic syndrome. Patients received regular single-dose rituximab (500 mg) intravenously every 6 months. Discontinuation of rituximab was considered after four to six doses if there was no recurrence of nephrotic syndrome. Glucocorticoid discontinuation with remission, first relapse after rituximab initiation, and relapse after regular rituximab treatment discontinuation were evaluated. RESULTS: The median age was 38 (range 18-67) years. Of 30 patients, 13 and 17 were men and women, respectively. Prior to rituximab treatment, the median number of nephrotic syndrome relapses in the patients was 5 (range 2- > 20). The 1 year discontinuation rate of glucocorticoids with remission was 83%. All patients discontinued glucocorticoid treatment at least once until 3 years and 7 months. The 1 and 2 year relapse rates after initiation of rituximab treatment were 0% and 3%, respectively. 25 patients discontinued regular rituximab treatment after a median number of six (4-12) doses. Six patients relapsed after discontinuing rituximab, and the 1 and 2 year relapse rates after the last regular rituximab treatment were 9% and 25%, respectively. CONCLUSION: All patients with steroid-dependent nephrotic syndrome who received rituximab could discontinue glucocorticoid treatment with remission, and three-fourths of the patients remained in remission for > 2 years after discontinuing rituximab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabNephrotic SyndromeRecurrenceGlucocorticoidsHumansMaleFemaleAdultRetrospective StudiesMiddle AgedYoung AdultAgedAdolescentTreatment OutcomeRemission InductionTime Factors

Stichwörter der Autor:innen

Focal segmental glomerulosclerosisGlucocorticoidMinimal change diseaseProteinuriaRemission

Substanzen

RituximabGlucocorticoids

Autor:innen und Institutionen

  • Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Morioka, Iwate, 020-0066, Japan.
  • Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Morioka, Iwate, 020-0066, Japan. inakaya@chuo-hp.jp.

Zitieren

APA

Saito, E., Oura, A., Kyo, T., Ishigaki, S., Kamei, H., Nakamura, Y., Soma, J., & Nakaya, I. (2024). Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02508-4

Vancouver

Saito E, Oura A, Kyo T, Ishigaki S, Kamei H, Nakamura Y, et al. Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02508-4

BibTeX
@article{Saito2024,
  author = {Saito, Eiichiro and Oura, Atsushi and Kyo, Tetsuya and Ishigaki, Shun and Kamei, Hitomi and Nakamura, Yuki and Soma, Jun and Nakaya, Izaya},
  title = {Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome},
  journal = {Clinical and Experimental Nephrology},
  year = {2024},
  doi = {10.1007/s10157-024-02508-4}
}
Kostenlos starten →